Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs First Citizens BancShares Inc (FCNCA) Price & Performance

Amgen, Inc.Trade
First Citizens BancShares IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs First Citizens BancShares Inc — how do they compare? Amgen, Inc. trades at $417.92 (market cap $225.15B), while First Citizens BancShares Inc trades at $2,270.44 (market cap $25.26B). The key difference: Amgen, Inc. is far larger — about 8.9× First Citizens BancShares Inc's market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

AMGNFCNCA
Market Cap
$225.15B$25.26B
Sector
HealthSector/Thematic
52-Week High
$417.20$2.27K
52-Week Low
$271.18$1.64K
Enterprise Value
$268.47B
Dividend Yield
2.42%0.37%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA